Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue
+1.44%
EPS
−21.5%
Free cash flow
−25.3%
Total debt
+3.04%

Quarter to September 2026, against a year earlier

42.73 1.91 −4.28%
Market cap
$64.7B
P/E
18.0×
Fwd P/E
17.0×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 7 8 7

+8 more TTM periods

ROE
14.15% 15.37% 14.69% 12.47%
ROA
7.94% 8.47% 8.44% 6.98%
ROIC
6.60% 6.96% 6.64% 6.65%
Return on Tangible Assets
55.02% 64.81% 43.60% 39.21%
Average Days of Receivables
53.93 53.01 53.60 53.20
Free Cash Flow per Share
2.30 2.47 2.34 2.47
Free Cash Flow
3,331.00 3,625.00 3,475.00 3,658.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026